{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:52:52Z","timestamp":1782755572768,"version":"3.54.5"},"reference-count":34,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ReGenTree, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin \u00df4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy. Complete healing occurred after 4 weeks in 6 of the 10 RGN-259-treated subjects and in 1 of the 8 placebo-treated subjects (p = 0.0656), indicating a strong efficacy trend. Additional efficacy was seen in the significant healing (p = 0.0359) with no recurrent defects observed at day 43, two weeks after cessation of treatment, while the one healed placebo-treated subject at day 28 suffered a recurrence at day 43. The Mackie classification disease stage improved in the RGN-259-treated group at Days 29, 36, and 43 (p = 0.0818, 0.0625, and 0.0467, respectively). Time to complete healing also showed a trend towards efficacy (p = 0.0829, Kaplan\u2013Meier) with 0.1% RGN-259. RGN-259-treated subjects had significant improvements at multiple time points in ocular discomfort, foreign body sensation, and dryness which were not seen in the placebo group. No significant adverse effects were observed. In summary, the use of 0.1% RGN-259 promotes rapid healing of epithelial defects in neurotrophic keratopathy, improves ocular comfort, and is safe for treating this challenging population of patients.<\/jats:p>","DOI":"10.3390\/ijms24010554","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T02:56:50Z","timestamp":1672282610000},"page":"554","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["0.1% RGN-259 (Thymosin \u00df4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-7327","authenticated-orcid":false,"given":"Gabriel","family":"Sosne","sequence":"first","affiliation":[{"name":"Kresge Eye Institute, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hynda K.","family":"Kleinman","sequence":"additional","affiliation":[{"name":"ReGenTree, LLC, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark","family":"Springs","sequence":"additional","affiliation":[{"name":"Eye Specialists of Indiana, Indianapolis, IN 46260, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Hollis","family":"Gross","sequence":"additional","affiliation":[{"name":"Cornea and Cataract Consultants of Arizona, Phoenix, AZ 85032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihye","family":"Sung","sequence":"additional","affiliation":[{"name":"HLB Therapeutics Co., Ltd., Seoul 13554, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2757-8112","authenticated-orcid":false,"given":"Shinwook","family":"Kang","sequence":"additional","affiliation":[{"name":"ReGenTree, LLC, Princeton, NJ 08540, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.eye.6700616","article-title":"Neurotrophic keratitis","volume":"17","author":"Bonini","year":"2003","journal-title":"Eye"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jtos.2020.09.007","article-title":"The molecular basis of neurotrophic keratopathy: Diagnostic and therapeutic implications. A review","volume":"19","year":"2021","journal-title":"Ocul. Surf."},{"key":"ref_3","first-page":"571","article-title":"Diagnosis and management of neurotrophic keratitis","volume":"8","author":"Sacchetti","year":"2014","journal-title":"Clin. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ophtha.2022.06.019","article-title":"Neurotrophic Keratopathy in the United States: An Intelligent Research in Sight Registry Analysis","volume":"129","author":"Bian","year":"2022","journal-title":"Ophthalmology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/07853890.2022.2045035","article-title":"Neurotrophic keratopathy: Current challenges and future prospects","volume":"54","author":"NaPier","year":"2022","journal-title":"Ann. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: A multicenter randomized vehicle-controlled pivotal trial","volume":"127","author":"Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"760507","DOI":"10.3389\/fphar.2021.760507","article-title":"Recombinant human nerve growth factor (cenegermin)-driven corneal wound healing process: An evidence-based analysis","volume":"12","author":"Bonzano","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"s139","DOI":"10.1517\/14712598.2015.1011617","article-title":"Advances in the basic and clinical applications of thymosin beta 4","volume":"15","author":"Goldstein","year":"2015","journal-title":"Exp. Opin. Biol. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1167\/iovs.15-16890","article-title":"Primary mechanisms of thymosin beta 4 repair activity in dry eye and other tissue disorders","volume":"56","author":"Sosne","year":"2015","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/exer.2001.1125","article-title":"Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury","volume":"74","author":"Sosne","year":"2002","journal-title":"Exp. Eye Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1167\/iovs.04-1368","article-title":"Thymosin beta 4 modulates corneal matrix-metalloproteinase levels and polymophonuclear cell infiltration after alkali injury","volume":"46","author":"Sosne","year":"2005","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_12","first-page":"1","article-title":"RGN-259 (thymosin beta 4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1016\/j.neuroscience.2009.09.054","article-title":"Neurological functional recovery after thymosin beta 4 treatment in mice with experimental auto encephalomyelitis","volume":"164","author":"Zhang","year":"2009","journal-title":"Neuroscience"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.nbd.2012.08.002","article-title":"Thymosin beta 4 promotes the recovery of peripheral neuropathy in type II diabetic mice","volume":"48","author":"Wang","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1749-6632.2012.06651.x","article-title":"Treatment of neurological injury with thymosin beta 4","volume":"1269","author":"Morris","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.neuropharm.2014.06.004","article-title":"Beneficial effects of thymosin beta 4 on spinal cord injury in the rat","volume":"85","author":"Cheng","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1749-6632.2010.05471.x","article-title":"Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4","volume":"1194","author":"Dunn","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_18","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: A randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE\u2122) model","volume":"9","author":"Sosne","year":"2015","journal-title":"Clin. Ophthal."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/bs.vh.2016.04.012","article-title":"Thymosin beta 4: A potential novel therapy for Neurotrophic Keratopathy, dry eye, and ocular surface diseases","volume":"102","author":"Sosne","year":"2016","journal-title":"Vitam. Horm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1196\/annals.1415.046","article-title":"Identification and quantification of thymosin beta 4 in human saliva and tears","volume":"1112","author":"Badamchian","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1021\/pr2004055","article-title":"Quantitative iTRAQ analysis of retinal ganglion cell degeneration after optic nerve crush","volume":"10","author":"Magharious","year":"2011","journal-title":"J. Proteome. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e3043","DOI":"10.1002\/jgm.3043","article-title":"Thymosin beta 4 suppresses CCL4-induced murine hepatic fibrosis by down-regulating transforming growth factor beta receptor-II","volume":"20","author":"Li","year":"2018","journal-title":"J. Gene. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/eci.12048","article-title":"Thymosin beta 4 protects C57BL\/6 mice from bleomycin-induced damage in the lung","volume":"43","author":"Conte","year":"2013","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/j.bbrc.2017.09.156","article-title":"Thymosin beta 4 attenuates liver fibrosis vis suppressing Notch signaling","volume":"493","author":"Hong","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10753-021-01528-6","article-title":"Thymosin beta 4 suppressed LPS-induced lung fibrosis by attenuating oxidative injury and alleviating inflammation","volume":"45","author":"Tian","year":"2022","journal-title":"Inflammation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1308651","DOI":"10.1155\/2022\/1308651","article-title":"Thymosin beta 4 protects against cardiac damage and subsequent cardiac fibrosis in mice with myocardial infarction","volume":"2022","author":"Wang","year":"2022","journal-title":"Cardiovasc. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14712598.2015.1026804","article-title":"Effects of thymosin beta 4 and its N-terminal fragment Ac-SDKP on TGF-beta treated human lung fibroblasts and in the mouse model of bleomycin-induced lung fibrosis","volume":"15","author":"Conte","year":"2018","journal-title":"Exp. Opin. Biol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.2174\/1381612821666150909093927","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP): Potential target molecule in research of heart, kidney, and brain","volume":"21","author":"Hrenak","year":"2015","journal-title":"Curr. Parm. Des."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1161\/01.HYP.0000100423.24330.96","article-title":"Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension","volume":"42","author":"Peng","year":"2003","journal-title":"Hypertension"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.1002\/iub.2389","article-title":"A long-acting isomer of Ac-SDKP attenuates pulmonary fibrosis through SRPK1-mediated P13\/AKT and Smad2 pathway inhibition","volume":"72","author":"Qui","year":"2020","journal-title":"IUBMB Life"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/01.HYP.0000107777.91185.89","article-title":"Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction","volume":"43","author":"Yang","year":"2004","journal-title":"Hypertension"},{"key":"ref_32","first-page":"5283","article-title":"Antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline on bile duct ligation induced liver fibrosis in rats","volume":"18","author":"Zhang","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/ki.2013.209","article-title":"Thymosin beta 4 and its degradation product, ac-SDKP, are novel reparative factors in renal fibrosis","volume":"84","author":"Zuo","year":"2013","journal-title":"Kidney Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/jdi.13219","article-title":"N-acetyl-seryl-aspartyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects","volume":"11","author":"Kanasaki","year":"2020","journal-title":"J. Diabetes Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/554\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:54:51Z","timestamp":1760147691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/1\/554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ijms24010554"],"URL":"https:\/\/doi.org\/10.3390\/ijms24010554","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}